Geoffrey C Nguyen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/997348/publications.pdf Version: 2024-02-01

		20797	32815
217	12,132	60	100
papers	citations	h-index	g-index
217	217	217	11489
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Periodic Colonoscopies Are Associated with Improved Survival and Prognosis of Colorectal Cancer in Ulcerative Colitis. Digestive Diseases and Sciences, 2022, 67, 1850-1857.	1.1	3
2	Risk Factors for Postpartum Disease Activity in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases, 2022, 28, 1090-1099.	0.9	11
3	Canadian Consensus Statements on the Transition of Adolescents and Young Adults with Inflammatory Bowel Disease from Pediatric to Adult Care: A Collaborative Initiative Between the Canadian IBD Transition Network and Crohn's and Colitis Canada. Journal of the Canadian Association of Gastroenterology. 2022. 5. 105-115.	0.1	8
4	Patient Experiences in the Management of Inflammatory Bowel Disease: A Qualitative Study. Journal of the Canadian Association of Gastroenterology, 2022, 5, 261-270.	0.1	3
5	Health Care Perspectives of Adult Patients with Lower Educational Attainment in Inflammatory Bowel Disease: A Qualitative Study. Journal of Patient Experience, 2022, 9, 237437352210925.	0.4	0
6	Persistent Diarrhea in Patients With Crohn's Disease After Mucosal Healing Is Associated With Lower Diversity of the Intestinal Microbiome and Increased Dysbiosis. Clinical Gastroenterology and Hepatology, 2021, 19, 296-304.e3.	2.4	19
7	Disease Activity in Inflammatory Bowel Disease Is Associated With Arterial Vascular Disease. Inflammatory Bowel Diseases, 2021, 27, 629-638.	0.9	18
8	AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review. Gastroenterology, 2021, 160, 445-451.	0.6	33
9	Variation in care of patients with elderly-onset inflammatory bowel disease in Ontario, Canada: A population-based cohort study. Journal of the Canadian Association of Gastroenterology, 2021, 4, e16-e30.	0.1	10
10	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD. Journal of the Canadian Association of Gastroenterology, 2021, 4, S34-S39.	0.1	2
11	Patient Perspectives of IBD Care and Services: An Integral Part of a Pan-Canadian Quality Improvement Initiative. Journal of the Canadian Association of Gastroenterology, 2021, 4, 229-233.	0.1	4
12	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. Journal of the Canadian Association of Gastroenterology, 2021, 4, S61-S67.	0.1	7
13	Impact of Digital Health Monitoring in the Management of Inflammatory Bowel Disease. Journal of Medical Systems, 2021, 45, 23.	2.2	14
14	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S1-S9.	0.1	5
15	Inflammatory Bowel Disease Increases the Risk of Venous Thromboembolism in Children: A Population-Based Matched Cohort Study. Journal of Crohn's and Colitis, 2021, 15, 2031-2040.	0.6	20
16	AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. Gastroenterology, 2021, 161, 1043-1051.e4.	0.6	102
17	Regional Variation in Pregnancy Outcomes amongst Women in Inflammatory Bowel Disease: A Population-Based Cohort Study. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-9.	0.8	4
18	Utilization of Diagnostic Imaging and Ionization Radiation Exposure Among an Inflammatory Bowel Disease Inception Cohort. Inflammatory Bowel Diseases, 2020, 26, 898-906.	0.9	9

#	Article	IF	CITATIONS
19	Integrated Care Models: Optimizing Adult Ambulatory Care in Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology, 2020, 3, 44-53.	0.1	14
20	Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. Journal of the Canadian Association of Gastroenterology, 2020, 3, 74-82.	0.1	6
21	Development of a Global Rating Scale for Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology, 2020, 3, 4-16.	0.1	2
22	ldentification of Target Golimumab Levels in Maintenance Therapy of Crohn's Disease and Ulcerative Colitis Associated With Mucosal Healing. Inflammatory Bowel Diseases, 2020, 26, 766-773.	0.9	7
23	Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population–Based Analysis. American Journal of Gastroenterology, 2020, 115, 128-137.	0.2	39
24	Primary Sclerosing Cholangitis in Children With Inflammatory Bowel Diseases Is Associated With Milder Clinical Activity But More Frequent Subclinical Inflammation and Growth Impairment. Clinical Gastroenterology and Hepatology, 2020, 18, 1509-1517.e7.	2.4	22
25	Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. The Cochrane Library, 2020, 8, CD012328.	1.5	7
26	Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review. American Journal of Gastroenterology, 2020, 115, 1768-1774.	0.2	11
27	Providing Hospitalized Ulcerative Colitis Patients With Practice Guidelines Improves Patient-Reported Outcomes. Journal of the Canadian Association of Gastroenterology, 2020, 4, 131-136.	0.1	4
28	Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. Journal of Crohn's and Colitis, 2020, 14, 1354-1363.	0.6	38
29	Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study. Inflammatory Bowel Diseases, 2020, 26, 1761-1768.	0.9	35
30	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. Angiology, 2020, 71, 689-697.	0.8	19
31	Inflammatory Bowel Disease Training During Adult Gastroenterology Residency: A National Survey of Canadian Program Directors and Trainees. Journal of the Canadian Association of Gastroenterology, 2019, 2, 118-125.	0.1	0
32	Transforming Access to Specialist Care for Inflammatory Bowel Disease: The PACE Telemedicine Program. Journal of the Canadian Association of Gastroenterology, 2019, 2, 186-194.	0.1	25
33	Paediatric to Adult Transition of Care in IBD: Understanding the Current Standard of Care Among Canadian Adult Academic Gastroenterologists. Journal of the Canadian Association of Gastroenterology, 2019, 3, 266-273.	0.1	4
34	The Impact of Private Insurance Access on Nonurgent Inflammatory Bowel Disease-Related Emergency Department Use. Crohn's & Colitis 360, 2019, 1, .	0.5	0
35	Rural and Urban Differences in the Risk of Inflammatory Bowel Disease and Subsequent Health Services Utilization in Ontario. Healthcare Quarterly (Toronto, Ont), 2019, 22, 6-9.	0.3	4
36	Predictive models of disease burden at diagnosis in persons with adult-onset ulcerative colitis using health administrative data. BMC Gastroenterology, 2019, 19, 13.	0.8	2

#	Article	IF	CITATIONS
37	The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care. Journal of the Canadian Association of Gastroenterology, 2019, 2, S34-S41.	0.1	31
38	The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1718-1728.	0.9	31
39	The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD. Journal of the Canadian Association of Gastroenterology, 2019, 2, S73-S80.	0.1	57
40	The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Journal of the Canadian Association of Gastroenterology, 2019, 2, S17-S33.	0.1	63
41	Hypoalbuminaemia and Postoperative Outcomes in Inflammatory Bowel Disease: the NSQIP Surgical Cohort. Journal of Crohn's and Colitis, 2019, 13, 1433-1438.	0.6	49
42	Ultrasound vs Endoscopy, Surgery, or Pathology for the Diagnosis of Small Bowel Crohn's Disease and its Complications. Inflammatory Bowel Diseases, 2019, 25, 1313-1338.	0.9	22
43	Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. Gastroenterology, 2019, 156, 1345-1353.e4.	0.6	273
44	Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Clinical Gastroenterology and Hepatology, 2019, 17, 1788-1798.e2.	2.4	23
45	The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors. Journal of the Canadian Association of Gastroenterology, 2019, 2, S68-S72.	0.1	29
46	The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology. Journal of the Canadian Association of Gastroenterology, 2019, 2, S6-S16.	0.1	95
47	Selection of Quality Indicators in IBD: Integrating Physician and Patient Perspectives. Inflammatory Bowel Diseases, 2019, 25, 403-409.	0.9	25
48	From mother to baby: antenatal exposure to monoclonal antibody biologics. Expert Review of Clinical Immunology, 2019, 15, 221-229.	1.3	29
49	The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn's and Colitis Canada. Journal of the Canadian Association of Gastroenterology, 2019, 2, S1-S5.	0.1	46
50	Inflammatory bowel disease and new-onset psychiatric disorders in pregnancy and post partum: a population-based cohort study. Gut, 2019, 68, 1597-1605.	6.1	29
51	The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD. Journal of the Canadian Association of Gastroenterology, 2019, 2, S49-S67.	0.1	70
52	Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology. Inflammatory Bowel Diseases, 2019, 25, 328-335.	0.9	7
53	Access to Specialists and Emergency Department Visits in Inflammatory Bowel Disease: A Population-Based Study. Journal of Crohn's and Colitis, 2019, 13, 330-336.	0.6	20
54	Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 818-823.	2.4	14

#	Article	IF	CITATIONS
55	Epidemiology and Risk Factors for Colorectal Cancer in Inflammatory Bowel Diseases. , 2019, , 1-15.		1
56	Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2018, 16, 1098-1105.e1.	2.4	35
57	Impact of experience on self-assessment accuracy of clinical colonoscopy competence. Gastrointestinal Endoscopy, 2018, 87, 827-836.e2.	0.5	24
58	A prospective comparison of live and video-based assessments of colonoscopy performance. Gastrointestinal Endoscopy, 2018, 87, 766-775.	0.5	34
59	The Bottom Line: A Multidisciplinary Approach Is Key to Treating Perianal Fistulizing Crohn's Disease. Journal of the Canadian Association of Gastroenterology, 2018, 1, 139-140.	0.1	Ο
60	Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. Clinical Epidemiology, 2018, Volume 10, 1613-1626.	1.5	48
61	Predictors of Cesarean Delivery in Pregnant Women with Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology, 2018, 1, 76-81.	0.1	23
62	Health Services Use during Transition from Pediatric to Adult Care for Inflammatory Bowel Disease: A Population-Based Study Using Health Administrative Data. Journal of Pediatrics, 2018, 203, 280-287.e4.	0.9	26
63	Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2018, 63, 2430-2438.	1.1	15
64	Reply. Gastroenterology, 2018, 154, 1203-1204.	0.6	0
65	The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease. Current Gastroenterology Reports, 2017, 19, 19.	1.1	7
66	Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases. American Journal of Gastroenterology, 2017, 112, 1120-1134.	0.2	241
67	Quality of Care and Outcomes Among Hospitalized Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 2017, 23, 695-701.	0.9	37
68	American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. Gastroenterology, 2017, 152, 1536-1543.	0.6	121
69	Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 858-865.	0.9	25
70	Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Digestive and Liver Disease, 2017, 49, 1086-1091.	0.4	23
71	Characterizing the Posttransfer Period Among Patients with Pediatric Onset IBD. Inflammatory Bowel Diseases, 2017, 23, 1483-1491.	0.9	14
72	Management of Crohn's Disease After Surgical Resection. Gastroenterology Clinics of North America, 2017, 46, 563-575.	1.0	10

#	Article	IF	CITATIONS
73	Risk of Surgery and Mortality in Elderly-onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 218-223.	0.9	77
74	American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology, 2017, 153, 827-834.	0.6	440
75	Use of Complementary and Alternative Medicine in Inflammatory Bowel Disease Around the World. Gastroenterology Clinics of North America, 2017, 46, 679-688.	1.0	25
76	Cost–utility Analysis. Inflammatory Bowel Diseases, 2017, 23, 1930-1940.	0.9	13
77	American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection. Gastroenterology, 2017, 152, 271-275.	0.6	178
78	Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology, 2017, 2017, 1-8.	0.8	13
79	Rural and Urban Residence During Early Life is Associated with Risk of Inflammatory Bowel Disease: A Population-Based Inception and Birth Cohort Study. American Journal of Gastroenterology, 2017, 112, 1412-1422.	0.2	88
80	Perspectives on endoscopic surveillance of dysplasia in inflammatory bowel disease: a survey of academic gastroenterologists. Endoscopy International Open, 2017, 05, E974-E979.	0.9	15
81	Microscopic Colitis: A Review of Collagenous and Lymphocytic Colitis. Gastroenterology and Hepatology, 2017, 13, 671-677.	0.2	9
82	Management of Inflammatory Bowel Disease in Pregnancy: A Practical Approach to New Guidelines. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-4.	0.8	5
83	Magnetic Resonance Imaging of the Small Bowel in Crohn's Disease: A Systematic Review and Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-14.	0.8	18
84	The Challenges of Living with Inflammatory Bowel Disease: Summary of a Summit on Patient and Healthcare Provider Perspectives. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-5.	0.8	25
85	Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease. Inflammatory Bowel Diseases, 2016, 22, 623-630.	0.9	136
86	Use of Complementary and Alternative Medicine for Inflammatory Bowel Disease Is Associated with Worse Adherence to Conventional Therapy. Inflammatory Bowel Diseases, 2016, 22, 1412-1417.	0.9	35
87	<i>Clostridium difficile</i> associated risk of death score (<scp>CARDS</scp>): a novel severity score to predict mortality among hospitalised patients with <i>C. difficile</i> infection. Alimentary Pharmacology and Therapeutics, 2016, 43, 725-733.	1.9	65
88	Quality Improvement Primer Series: Launching a Quality Improvement Initiative. Clinical Gastroenterology and Hepatology, 2016, 14, 1067-1071.	2.4	8
89	Quality Improvement Primer Series: The Plan-Do-Study-Act Cycle and Data Display. Clinical Gastroenterology and Hepatology, 2016, 14, 1230-1233.	2.4	9
90	Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study. American Journal of Gastroenterology, 2016, 111, 1141-1146.	0.2	104

#	Article	IF	CITATIONS
91	First Do No Harm: Is It Safe to Use Immunosuppressants in Inflammatory Bowel Disease Patients With Prior Cancer?. Gastroenterology, 2016, 151, 22-24.	0.6	4
92	Therapeutic challenges of managing inflammatory bowel disease in the elderly patient. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1005-1010.	1.4	7
93	"Just in Time― When Is It SafeÂto Administer Live Vaccines to Infants Exposed toÂAnti-Tumor Necrosis Factor Agents In Utero?. Gastroenterology, 2016, 151, 1249-1250.	0.6	11
94	Development of the Harvey-Bradshaw Index-pro (HBI-PRO) Score to Assess Endoscopic Disease Activity in Crohn's Disease. Journal of Crohn's and Colitis, 2016, 11, jjw200.	0.6	35
95	Preoperative Anti–tumor Necrosis Factor Therapy in Patients with Ulcerative Colitis Is Not Associated with an Increased Risk of Infectious and Noninfectious Complications After Ileal Pouch–anal Anastomosis. Inflammatory Bowel Diseases, 2016, 22, 2442-2447.	0.9	38
96	Health Services Utilization, Specialist Care, and Time to Diagnosis with Inflammatory Bowel Disease in Immigrants to Ontario, Canada. Inflammatory Bowel Diseases, 2016, 22, 2482-2490.	0.9	28
97	Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease. Journal of Crohn's and Colitis, 2016, 10, 510-515.	0.6	77
98	Increased Risk of Venous Thromboembolic Events With Corticosteroid Versus Biologic Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 166-167.	2.4	2
99	Perceptions and Attitudes Towards Medication Adherence during Pregnancy in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 892-897.	0.6	54
100	Increased Postoperative Mortality and Complications Among Elderly Patients With Inflammatory Bowel Diseases: An Analysis of the National Surgical Quality Improvement Program Cohort. Clinical Gastroenterology and Hepatology, 2016, 14, 1274-1281.	2.4	69
101	The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology, 2016, 150, 734-757.e1.	0.6	373
102	American Gastroenterological Association Institute Guideline on the Medical Management of Microscopic Colitis. Gastroenterology, 2016, 150, 242-246.	0.6	144
103	Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 2090-2096.	0.9	25
104	Predictors of Outcome in Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 2097-2105.	0.9	40
105	Asthma, Type 1 and Type 2 Diabetes Mellitus, and Inflammatory Bowel Disease amongst South Asian Immigrants to Canada and Their Children: A Population-Based Cohort Study. PLoS ONE, 2015, 10, e0123599.	1.1	46
106	Transitioning the Adolescent with IBD from Pediatric to Adult Care: A Review of the Literature. Gastroenterology Research and Practice, 2015, 2015, 1-7.	0.7	32
107	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. Gastroenterology, 2015, 148, 1035-1058.e3.	0.6	323
108	Diverticular Disease: Changing Epidemiology and Management. Drugs and Aging, 2015, 32, 349-360.	1.3	13

#	Article	IF	CITATIONS
109	Inflammatory Bowel Disease in Immigrants to Canada And Their Children: A Population-Based Cohort Study. American Journal of Gastroenterology, 2015, 110, 553-563.	0.2	194
110	Vaccination in Inflammatory Bowel Disease Patients: Attitudes, Knowledge, and Uptake. Journal of Crohn's and Colitis, 2015, 9, 439-444.	0.6	80
111	Health Care Utilization in Elderly Onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 777-782.	0.9	37
112	Gastrointestinal Endoscopy Competency Assessment Tool: reliability and validity evidence. Gastrointestinal Endoscopy, 2015, 81, 1417-1424.e2.	0.5	47
113	Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. World Journal of Gastroenterology, 2015, 21, 1251.	1.4	37
114	A Survey of Perceptions and Practices of Complementary Alternative Medicine among Canadian Gastroenterologists. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 45-49.	0.8	11
115	Defining Quality Indicators for Best-Practice Management of Inflammatory Bowel Disease in Canada. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 275-285.	0.8	50
116	Non-invasive diagnosis of advanced fibrosis and cirrhosis. World Journal of Gastroenterology, 2014, 20, 16820.	1.4	146
117	The impact of preoperative steroid use on short-term outcomes following surgery for inflammatory bowel disease. Journal of Crohn's and Colitis, 2014, 8, 1661-1667.	0.6	87
118	The Impact of Surgeon Volume on Postoperative Outcomes After Surgery for Crohn's Disease. Inflammatory Bowel Diseases, 2014, 20, 301-306.	0.9	31
119	Changing Age Demographics of Inflammatory Bowel Disease in Ontario, Canada. Inflammatory Bowel Diseases, 2014, 20, 1761-1769.	0.9	166
120	Practices and attitudes toward complementary and alternative medicine in inflammatory bowel disease: a survey of gastroenterologists. Journal of Complementary and Integrative Medicine, 2014, 11, 297-303.	0.4	9
121	Factors Associated With Readmissions and Outcomes of Patients Hospitalized for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 1897-1904.e1.	2.4	39
122	Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada. Journal of Clinical Epidemiology, 2014, 67, 887-896.	2.4	157
123	Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology. Gastroenterology, 2014, 146, 835-848.e6.	0.6	277
124	The effect of underlying liver disease on short-term outcomes following bariatric surgery. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 2708-2712.	1.3	20
125	Incidence, Outcomes, and Health Services Burden of Very Early Onset Inflammatory Bowel Disease. Gastroenterology, 2014, 147, 803-813.e7.	0.6	222
126	National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. Journal of Crohn's and Colitis, 2014, 8, 288-295.	0.6	157

#	Article	IF	CITATIONS
127	Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States. Inflammatory Bowel Diseases, 2014, 20, 398-415.	0.9	33
128	Racial Disparities in Mortality in Patients Undergoing Bariatric Surgery in the USA. Obesity Surgery, 2013, 23, 1508-1514.	1.1	62
129	Duration of Anticoagulation for the Management of Venous Thromboembolism in Inflammatory Bowel Disease: A Decision Analysis. American Journal of Gastroenterology, 2013, 108, 1486-1495.	0.2	22
130	Physicians' Perceptions of Risks and Practices in Venous Thromboembolism Prophylaxis in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2013, 58, 46-52.	1.1	43
131	Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients. Journal of Crohn's and Colitis, 2013, 7, e479-e485.	0.6	80
132	Patient awareness of extraintestinal manifestations of inflammatory bowel disease. Journal of Crohn's and Colitis, 2013, 7, e318-e324.	0.6	28
133	Postoperative VTE prophylaxis in IBD. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 5-6.	8.2	10
134	Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut, 2013, 62, 387-394.	6.1	113
135	Feasibility of Venous Thromboembolism Prophylaxis During Inflammatory Bowel Disease Flares in the Outpatient Setting. Inflammatory Bowel Diseases, 2013, 19, 2182-2189.	0.9	16
136	The Utility of Screening for Asymptomatic Lower Extremity Deep Venous Thrombosis during Inflammatory Bowel Disease Flares. Inflammatory Bowel Diseases, 2013, 19, 1053-1058.	0.9	16
137	Employment Prospects and Trends for Gastroenterology Trainees in Canada: A Nationwide Survey. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 647-652.	1.8	4
138	Hepatitis C as a Prognostic Indicator among Noncirrhotic Patients Hospitalized with Alcoholic Hepatitis. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 639-642.	1.8	4
139	Prevalence and Incidence of Antimicrobial-Resistant Organisms among Hospitalized Inflammatory Bowel Disease Patients. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, e117-e121.	0.7	8
140	Younger Age and Prognosis in Diverticulitis: A Nationwide Retrospective Cohort Study. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 95-98.	1.8	7
141	Quality of care delivered to hospitalized inflammatory bowel disease patients. World Journal of Gastroenterology, 2013, 19, 6360.	1.4	15
142	Quality improvement in pediatric inflammatory bowel disease: Moving forward to improve outcomes. World Journal of Gastroenterology, 2013, 19, 6367.	1.4	8
143	Interventions and targets aimed at improving quality in inflammatory bowel disease ambulatory care. World Journal of Gastroenterology, 2013, 19, 6375.	1.4	8
144	Presence of phthalates in gastrointestinal medications: Is there a hidden danger?. World Journal of Gastroenterology, 2013, 19, 7042.	1.4	33

#	Article	IF	CITATIONS
145	Impact of gastroenterologist care on health outcomes of hospitalised ulcerative colitis patients. Gut, 2012, 61, 1410-1416.	6.1	39
146	Postoperative Health-Care Utilization in Crohn's Disease: The Impact of Specialist Care. American Journal of Gastroenterology, 2012, 107, 1522-1529.	0.2	15
147	Tip of the iceberg?. Gut Microbes, 2012, 3, 434-436.	4.3	6
148	Trends in Canadian hospital standardised mortality ratios and palliative care coding 2004–2010: a retrospective database analysis. BMJ Open, 2012, 2, e001729.	0.8	12
149	Postoperative complications following colectomy for ulcerative colitis: A validation study. BMC Gastroenterology, 2012, 12, 39.	0.8	56
150	Impact of <i>Clostridium difficile</i> colitis on 5â€year health outcomes in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2012, 36, 1032-1039.	1.9	67
151	A Tale of Two Cohorts: Are We Overestimating the Risk of Colorectal Cancer in Inflammatory Bowel Disease?. Gastroenterology, 2012, 143, 288-290.	0.6	14
152	Prevalence and predictors of MRSA, ESBL, and VRE colonization in the ambulatory IBD population. Journal of Crohn's and Colitis, 2012, 6, 743-749.	0.6	20
153	Early cholecystectomy and ERCP are associated with reduced readmissions for acute biliary pancreatitis: a nationwide, population-based study. Gastrointestinal Endoscopy, 2012, 75, 47-55.	0.5	46
154	5-Aminosalicylic Acid Is Not Protective Against Colorectal Cancer in Inflammatory Bowel Disease: A Meta-Analysis of Non-Referral Populations. American Journal of Gastroenterology, 2012, 107, 1298-1304.	0.2	91
155	Survey of Perceptions and Practices among Canadian Gastroenterologists regarding the Prevention of Venous Thromboembolism for Hospitalized Inflammatory Bowel Disease Patients. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 795-798.	1.8	18
156	Contribution of higher risk genes and European admixture to Crohn's disease in African Americans. Inflammatory Bowel Diseases, 2012, 18, 2277-2287.	0.9	29
157	Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2012, 35, 342-349.	1.9	92
158	Treatment of thromboembolism in IBD: More questions than answers. Inflammatory Bowel Diseases, 2012, 18, 172-173.	0.9	3
159	Increased Perioperative Mortality Following Bariatric Surgery Among Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2011, 9, 897-901.	2.4	217
160	Outcomes of Patients With Crohn's Disease Improved From 1988 to 2008 and Were Associated With Increased Specialist Care. Gastroenterology, 2011, 141, 90-97.	0.6	161
161	Diverticular Disease: Epidemiology and Management. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 385-389.	1.8	250
162	Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. Pharmacoepidemiology and Drug Safety, 2011, 20, 838-848.	0.9	27

#	Article	IF	CITATIONS
163	Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile. Inflammatory Bowel Diseases, 2011, 17, 1540-1546.	0.9	75
164	Increased risk of vancomycin-resistant enterococcus (VRE) infection among patients hospitalized for inflammatory bowel disease in the United States. Inflammatory Bowel Diseases, 2011, 17, 1338-1342.	0.9	26
165	Venous Thromboembolism in Inflammatory Bowel Disease: An Epidemiological Review. American Journal of Gastroenterology, 2011, 106, 713-718.	0.2	169
166	Risk of Comorbidities on Postoperative Outcomes in Patients With Inflammatory Bowel Disease. Archives of Surgery, 2011, 146, 959.	2.3	66
167	Bugs and Drugs: Insights into the Pathogenesis of Inflammatory Bowel Disease. American Journal of Gastroenterology, 2011, 106, 2143-2145.	0.2	19
168	Epidemiological trends and geographic variation in hospital admissions for diverticulitis in the United States. World Journal of Gastroenterology, 2011, 17, 1600.	1.4	116
169	Hospital Volume as a Predictor for Undergoing Cholecystectomy After Admission for Acute Biliary Pancreatitis. Pancreas, 2010, 39, e42-e47.	0.5	41
170	Impact of Diabetes on Postoperative Outcomes Following Colon Cancer Surgery. Journal of General Internal Medicine, 2010, 25, 809-813.	1.3	21
171	Quality and publication success of abstracts of randomized clinical trials in inflammatory bowel disease presented at Digestive Disease Weekâ€. Inflammatory Bowel Diseases, 2010, 16, 993-998.	0.9	9
172	NOD2 Mutations and Anti- Saccharomyces cerevisiae Antibodies Are Risk Factors for Crohn's Disease in African Americans. American Journal of Gastroenterology, 2010, 105, 378-386.	0.2	30
173	Racial Disparities in Utilization of Specialist Care and Medications in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2010, 105, 2202-2208.	0.2	84
174	Increased Prevalence of and Associated Mortality With Methicillin-Resistant Staphylococcus aureus Among Hospitalized IBD Patients. American Journal of Gastroenterology, 2010, 105, 371-377.	0.2	40
175	Liver Cirrhosis Is Associated With Venous Thromboembolism Among Hospitalized Patients in a Nationwide US Study. Clinical Gastroenterology and Hepatology, 2010, 8, 800-805.e1.	2.4	134
176	Endoscopic management and outcomes of pregnant women hospitalized for nonvariceal upper GI bleeding: a nationwide analysis. Gastrointestinal Endoscopy, 2010, 72, 954-959.	0.5	10
177	Prophylaxis of venous thromboembolism in IBD. Lancet, The, 2010, 375, 616-617.	6.3	11
178	Colon cancer screening in 2010: an up-date. Minerva Gastroenterologica E Dietologica, 2010, 56, 181-8.	2.2	15
179	Phenotypic and Genotypic Characteristics of Inflammatory Bowel Disease in French Canadians: Comparison With a Large North American Repository. American Journal of Gastroenterology, 2009, 104, 2233-2240.	0.2	23
180	Prediction of the Need for Surgical Intervention in Obstructive Crohn's Disease by ¹⁸ F-FDG PET/CT. Journal of Nuclear Medicine, 2009, 50, 1751-1759.	2.8	67

#	Article	IF	CITATIONS
181	Racial and Geographic Disparities in the Use of Parenteral Nutrition Among Inflammatory Bowel Disease Inpatients Diagnosed With Malnutrition in the United States. Journal of Parenteral and Enteral Nutrition, 2009, 33, 563-568.	1.3	22
182	Hospitalizations for inflammatory bowel disease: Profile of the uninsured in the United States. Inflammatory Bowel Diseases, 2009, 15, 726-733.	0.9	20
183	Inflammatory bowel disease patients who leave hospital against medical advice: Predictors and temporal trends. Inflammatory Bowel Diseases, 2009, 15, 845-851.	0.9	29
184	Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease. Inflammatory Bowel Diseases, 2009, 15, 1233-1239.	0.9	154
185	Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus. Liver Transplantation, 2009, 15, 754-762.	1.3	24
186	Volumes of liver transplant and partial hepatectomy procedures are independently associated with lower postoperative mortality following resection for hepatocellular carcinoma. Liver Transplantation, 2009, 15, 776-781.	1.3	16
187	Protein–calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. Liver International, 2009, 29, 1396-1402.	1.9	148
188	Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis. Gastrointestinal Endoscopy, 2009, 69, 1299-1310.	0.5	32
189	Is Keeping the Colon the Ultimate Marker of Success in Ulcerative Colitis?. Gastroenterology, 2009, 137, 1204-1206.	0.6	7
190	Health-state utilities in a prisoner population: a cross-sectional survey. Health and Quality of Life Outcomes, 2009, 7, 78.	1.0	8
191	Outcomes of Obstetric Hospitalizations Among Women With Inflammatory Bowel Disease in the United States. Clinical Gastroenterology and Hepatology, 2009, 7, 329-334.	2.4	126
192	Impact of Cirrhosis and Liver Transplant on Maternal Health During Labor and Delivery. Clinical Gastroenterology and Hepatology, 2009, 7, 1367-1372.e1.	2.4	34
193	The Impact of Cirrhosis and Portal Hypertension on Mortality Following Colorectal Surgery: A Nationwide, Population-Based Study. Diseases of the Colon and Rectum, 2009, 52, 1367-1374.	0.7	83
194	Community-based Health Preferences for Proctocolectomy: A Race Comparison. Digestive Diseases and Sciences, 2008, 53, 741-746.	1.1	4
195	Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflammatory Bowel Diseases, 2008, 14, 1105-1111.	0.9	162
196	Nationwide patterns of hospitalizations to centers with high volume of admissions for inflammatory bowel disease and their impact on mortality. Inflammatory Bowel Diseases, 2008, 14, 1688-1694.	0.9	57
197	Racial disparity in liver disease: Biological, cultural, or socioeconomic factors. Hepatology, 2008, 47, 1058-1066.	3.6	135
198	Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States: A nationwide analysis. Hepatology, 2008, 48, 1336-1341.	3.6	92

#	Article	IF	CITATIONS
199	Is there a gender difference in the prevalence of Crohn's disease or ulcerative colitis?. Inflammatory Bowel Diseases, 2008, 14, S2-S3.	0.9	32
200	A National Survey of the Prevalence and Impact of Clostridium difficile Infection Among Hospitalized Inflammatory Bowel Disease Patients. American Journal of Gastroenterology, 2008, 103, 1443-1450.	0.2	368
201	Race Is a Predictor of In-Hospital Mortality After Cholecystectomy, Especially in Those With Portal Hypertension. Clinical Gastroenterology and Hepatology, 2008, 6, 1146-1154.	2.4	14
202	Racial Disparities in Cholecystectomy Rates During Hospitalizations for Acute Gallstone Pancreatitis: A National Survey. American Journal of Gastroenterology, 2008, 103, 2301-2307.	0.2	55
203	Rising Prevalence of Venous Thromboembolism and Its Impact on Mortality Among Hospitalized Inflammatory Bowel Disease Patients. American Journal of Gastroenterology, 2008, 103, 2272-2280.	0.2	306
204	Nationwide Increase in Hospitalizations and Hepatitis C Among Inpatients With Cirrhosis and Sequelae of Portal Hypertension. Clinical Gastroenterology and Hepatology, 2007, 5, 1092-1099.	2.4	81
205	Outcomes of patients with cirrhosis undergoing non-hepatic surgery: Risk assessment and management. World Journal of Gastroenterology, 2007, 13, 4056.	1.4	118
206	Assessment of reliability and validity of IBD phenotyping within the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) IBD Genetics Consortium (IBDGC). Inflammatory Bowel Diseases, 2007, 13, 975-983.	0.9	38
207	Race and health insurance are predictors of hospitalized Crohn's disease patients undergoing bowel resection. Inflammatory Bowel Diseases, 2007, 13, 1408-1416.	0.9	83
208	Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004#. Inflammatory Bowel Diseases, 2007, 13, 1529-1535.	0.9	140
209	Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: A national study. Hepatology, 2007, 45, 1282-1289.	3.6	88
210	Minimizing risk associated with elderly liver donors by matching to preferred recipients. Hepatology, 2007, 46, 1907-1918.	3.6	87
211	Reply:. Hepatology, 2007, 47, 360-360.	3.6	1
212	Twenty years of liver transplantation for Budd-Chiari syndrome: A national registry analysis. Liver Transplantation, 2007, 13, 1285-1294.	1.3	99
213	Racial and Geographic Variations in Colectomy Rates Among Hospitalized Ulcerative Colitis Patients. Clinical Gastroenterology and Hepatology, 2006, 4, 1507-1513.e1.	2.4	89
214	Back to school: training a new generation of clinical investigators. Gastrointestinal Endoscopy, 2006, 64, 96-97.	0.5	0
215	Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease. Current Gastroenterology Reports, 2006, 8, 499-505.	1.1	11
216	Inflammatory Bowel Disease Characteristics Among African Americans, Hispanics, and Non-Hispanic Whites: Characterization of a Large North American Cohort. American Journal of Gastroenterology, 2006, 101, 1012-1023.	0.2	255

#	Article	IF	CITATIONS
217	Exhaled nitric oxide: a marker of pulmonary hemodynamics in heart failure. Journal of the American College of Cardiology, 2002, 40, 1114-1119.	1.2	26